Basic and clinical studies on BMY-28100 in urology

Yoshitsugu Nasu; Daisuke Yamada; Masaya Tsugawa; Mikio Kishi; Hiromi Kumon; Hiroyuki Ohmori; Katsuichi Nanba; Nobuyuki Akazawa; Akihiro Mizuno

doi:10.11250/chemotherapy1953.37.Supplement3_606

Basic and clinical studies on BMY-28100 in urology

Yoshitsugu Nasu, Daisuke Yamada, Masaya Tsugawa, Mikio Kishi, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Nobuyuki Akazawa, Akihiro Mizuno

Research output: Contribution to journal › Article › peer-review

Abstract

We performed basic and clinical studies on BMY-28100, a new orally active antimicrobial agent, in urology. 1) BMY-28100 had a broad spectrum, showing strong antibacterial activity against Gram-positive bacteria, includingStaphylococcus aureus, Staphylococcus epidermidis and Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniaeand Proteus mirabilis 2) Two patients with acute uncomplicated cystitis showed excellent or good response to BMY-28100 treatment. Six of 14 patients with complicated urinary tract infection showed excellent or moderateresponse. 3) No side effects were observed. Abnormal laboratory findings were noted in 5 episodes in 3 patients, but were mild and transient.

Original language	English
Pages (from-to)	606-618
Number of pages	13
Journal	CHEMOTHERAPY
Volume	37
DOIs	https://doi.org/10.11250/chemotherapy1953.37.Supplement3_606
Publication status	Published - Jan 1 1989

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.37.Supplement3_606

Cite this

@article{d022872216e143038c220e662d8f0d18,

title = "Basic and clinical studies on BMY-28100 in urology",

abstract = "We performed basic and clinical studies on BMY-28100, a new orally active antimicrobial agent, in urology. 1) BMY-28100 had a broad spectrum, showing strong antibacterial activity against Gram-positive bacteria, includingStaphylococcus aureus, Staphylococcus epidermidis and Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniaeand Proteus mirabilis 2) Two patients with acute uncomplicated cystitis showed excellent or good response to BMY-28100 treatment. Six of 14 patients with complicated urinary tract infection showed excellent or moderateresponse. 3) No side effects were observed. Abnormal laboratory findings were noted in 5 episodes in 3 patients, but were mild and transient.",

author = "Yoshitsugu Nasu and Daisuke Yamada and Masaya Tsugawa and Mikio Kishi and Hiromi Kumon and Hiroyuki Ohmori and Katsuichi Nanba and Nobuyuki Akazawa and Akihiro Mizuno",

year = "1989",

month = jan,

day = "1",

doi = "10.11250/chemotherapy1953.37.Supplement3_606",

language = "English",

volume = "37",

pages = "606--618",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on BMY-28100 in urology

AU - Nasu, Yoshitsugu

AU - Yamada, Daisuke

AU - Tsugawa, Masaya

AU - Kishi, Mikio

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Nanba, Katsuichi

AU - Akazawa, Nobuyuki

AU - Mizuno, Akihiro

PY - 1989/1/1

Y1 - 1989/1/1

N2 - We performed basic and clinical studies on BMY-28100, a new orally active antimicrobial agent, in urology. 1) BMY-28100 had a broad spectrum, showing strong antibacterial activity against Gram-positive bacteria, includingStaphylococcus aureus, Staphylococcus epidermidis and Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniaeand Proteus mirabilis 2) Two patients with acute uncomplicated cystitis showed excellent or good response to BMY-28100 treatment. Six of 14 patients with complicated urinary tract infection showed excellent or moderateresponse. 3) No side effects were observed. Abnormal laboratory findings were noted in 5 episodes in 3 patients, but were mild and transient.

AB - We performed basic and clinical studies on BMY-28100, a new orally active antimicrobial agent, in urology. 1) BMY-28100 had a broad spectrum, showing strong antibacterial activity against Gram-positive bacteria, includingStaphylococcus aureus, Staphylococcus epidermidis and Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniaeand Proteus mirabilis 2) Two patients with acute uncomplicated cystitis showed excellent or good response to BMY-28100 treatment. Six of 14 patients with complicated urinary tract infection showed excellent or moderateresponse. 3) No side effects were observed. Abnormal laboratory findings were noted in 5 episodes in 3 patients, but were mild and transient.

UR - http://www.scopus.com/inward/record.url?scp=0024894072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024894072&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.37.Supplement3_606

DO - 10.11250/chemotherapy1953.37.Supplement3_606

M3 - Article

AN - SCOPUS:0024894072

SN - 0009-3165

VL - 37

SP - 606

EP - 618

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Basic and clinical studies on BMY-28100 in urology

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this